LN2, CD10, and Ezrin Do Not Distinguish Between Atypical Fibroxanthoma and Undifferentiated Pleomorphic Sarcoma or Predict Clinical Outcome

Autor: Thomas Stasko, Allison Hanlon, Nika Cyrus, Anjela Galan, Dan Christiansen
Rok vydání: 2017
Předmět:
Adult
Male
Pathology
medicine.medical_specialty
Skin Neoplasms
medicine.medical_treatment
Histiocytoma
Malignant Fibrous
Dermatology
Sensitivity and Specificity
Undifferentiated Pleomorphic Sarcoma
Diagnosis
Differential
Hospitals
University
030207 dermatology & venereal diseases
03 medical and health sciences
0302 clinical medicine
Ezrin
Predictive Value of Tests
Biomarkers
Tumor
Mohs surgery
Humans
Medicine
Neoplasm
Aged
Retrospective Studies
Aged
80 and over
business.industry
Poorly differentiated
Histocompatibility Antigens Class II
Follow up studies
Atypical fibroxanthoma
Sarcoma
General Medicine
Middle Aged
Mohs Surgery
medicine.disease
Survival Analysis
United States
Antigens
Differentiation
B-Lymphocyte
Cytoskeletal Proteins
Treatment Outcome
Multicenter study
030220 oncology & carcinogenesis
Female
Neprilysin
Surgery
business
Follow-Up Studies
Zdroj: Dermatologic Surgery. 43:431-436
ISSN: 1524-4725
1076-0512
DOI: 10.1097/dss.0000000000001000
Popis: Atypical fibroxanthoma (AFX) is a rare cutaneous spindled cell neoplasm. For both diagnostic and therapeutic purposes, it is important to distinguish AFX from other poorly differentiated tumors, including undifferentiated pleomorphic sarcoma (UPS).The authors aimed to identify the clinical, histologic, and immunohistochemical expression of LN2, ezrin, and CD10 in AFX and UPS tumors.The authors retrospectively examined the charts of patients with AFX and UPS treated with Mohs micrographic surgery (MMS) at 2 academic institutions. Patient demographics, tumor characteristics, and clinical course data were collected. Immunohistochemical stains were performed on primary and recurrent AFX and UPS tumors with monoclonal antibodies against the B-cell marker LN2 (CD74), CD10, and ezrin.In the series of 169 patients with AFX included in this study, local recurrence was rare at 3%. In contrast, the seven patients with UPS had an aggressive clinical course with 1 local recurrence and 2 distant metastases. Immunohistochemistry staining for ezrin, LN2, and CD10 were similar in AFX and UPS tumors.AFX can be treated with MMS with rare instances of recurrence. Undifferentiated pleomorphic sarcoma has a more aggressive clinical course with increased risk for recurrence and metastasis. Staining with ezrin, LN2, and CD10 did not differentiate AFX or UPS tumors.
Databáze: OpenAIRE
Externí odkaz: